Medicines and Healthcare products Regulatory Agency
Regulatory Agency
- MHRA guidance on Coronavirus (COVID-19)
- MHRA guidance on transition
- Drug and device alerts
- Drug Safety Update
- Yellow Card: Report a problem with a medicine or medical device
- Marketing authorisations and licensing guidance
- Patient information leaflets and summaries of product characteristics
- Public assessment reports
- Medical devices regulation and safety
- Contact MHRA
- All MHRA services and information
Featured
This new combination treatment is for people with mild to moderate COVID-19 who are at high risk of developing severe COVID-19
MHRA approves Xevudy (sotrovimab), a COVID-19 treatment found to cut hospitalisation and death by 79%
Press release
This monoclonal antibody – the second to be authorised by the Medicines and Healthcare products Regulatory Agency – is for people with mild to moderate COVID-19 who are at high risk of developing severe disease.
Coronavirus (COVID-19) vaccines adverse reactions
Research and analysis
A weekly report covering adverse reactions to approved COVID-19 vaccines
A new paediatric formulation of the Pfizer BioNTech COVID-19 vaccine has been approved for children aged 5 to 11 after meeting the required safety, quality and effectiveness standards.
The different types of tests and testing kits for COVID-19, and the specifications for manufacturers.
The antiviral was found to be safe and effective following a stringent review of the available evidence.
Latest from the Medicines and Healthcare products Regulatory Agency
What the Medicines and Healthcare products Regulatory Agency does
The Medicines and Healthcare products Regulatory Agency regulates medicines, medical devices and blood components for transfusion in the UK.
MHRA is an executive agency, sponsored by the Department of Health and Social Care.
Follow us
Documents
Policy papers and consultations
- MHRA draft guidance on randomised controlled trials generating real-world evidence to support regulatory decisions
- Access Consortium statement on COVID-19 medicines
Transparency and freedom of information releases
- Clinical trials for medicines: authorisation assessment performance
- MHRA: requests under the Freedom of Information Act (FOIA)
Our management
Contact MHRA
General enquiries
10 South Colonnade
London
E14 4PU
United Kingdom
Telephone
020 3080 6000
Fax
020 3118 9803
Please get in touch with us by phone or email during the coronavirus (COVID-19) response period.
Office hours are Monday to Friday, 9am to 5pm.
Media enquiries
MHRA
10 South Colonnade
London
E14 4PU
United Kingdom
During office hours:
020 3080 7651 (08:30 - 17:00)
Out of office hours:
07770 446 189 (17:00 - 08:30)
Office hours are Monday to Friday, 8:30am to 5pm. For real-time updates including the latest press releases and news statements, see our Twitter channel at https://www.twitter.com/mhragovuk
Make an FOI request
- Read about the Freedom of Information (FOI) Act and how to make a request.
- Check our previous releases to see if we’ve already answered your question.
- Make a new request by contacting us using the details below.
Freedom of Information
10 South Colonnade
London
E14 4PU
United Kingdom
Due to the COVID-19 pandemic we strongly encourage any requests to be made electronically to info@mhra.gov.uk.
Corporate information
Jobs and contracts